4 results
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.
Primary Objective: Assess the incidence of wound infections in patients treated with venous stenting and AV fistula and Prevena negative pressure wound therapy (NPWT).Secondary Objective(s): Assess the incidence of lymph leakage in patients treated…
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.